
When performance goes sideways, automated bioprocesses need a manual fallback state, according to Gaurav Walia at @PQEGroup, who writes about narrowing the gap between advisory and closed loop models. bioprocessonline.com/doc/clo…

Providing biopharmaceutical professionals with timely insights from field experts, including the latest best practices in upstream and downstream processes.

When performance goes sideways, automated bioprocesses need a manual fallback state, according to Gaurav Walia at @PQEGroup, who writes about narrowing the gap between advisory and closed loop models. bioprocessonline.com/doc/clo…

So many acronyms, so many different manufacturing problems. Robert Dream sorts the ADCs from the AOCs from the ATMPs, and explains why no single development strategy covers them. bioprocessonline.com/doc/com…

Apparently, "continuous bioprocessing" is old news. AstraZeneca's executive director of bioprocess technology and engineering, Jon Coffman, Ph.D., prefers the term "Integrated Dynamic Bioprocessing." Read more to find out why: bioprocessonline.com/doc/the…

Biopharmaceutical packaging has some non-negotiable attributes, and they can limit sustainability efforts. @josesaizmonzon says reducing packaging footprint boils down to two objectives: preserving the goods inside and maintaining compliance. bioprocessonline.com/doc/wan…

Bioprocess Online Live, Nov. 17, explores the current and future state of predictive control in biopharmaceutical manufacturing. Register for free. Sign up today: event.on24.com/wcc/r/5512381…

Closing The CAR-T Access Gap With Hospital-Based Manufacturing - @BoroDropulic, @caring_cross/VectorBioMed for @_CellandGene cellandgene.com/doc/closing-…

Flawed individual AI outputs might seem plausible until you trend them. The latest Annex 22 draft aims to rein in the gap between single items and the whole process. Sachin Bhandari at TrustBridge Compliance breaks it down. bioprocessonline.com/doc/wha…

Big bang: a complex system change or upgrade that happens all at once with no option to rollback. @Roche leaders explained one such cutover involving three integrated systems at a fill/finish site in Kaiseraugst. bioprocessonline.com/doc/how…

Clonal cell line selection can take weeks (or longer), and that's why people like Susan Sharfstein, Ph.D., are devising ways to accelerate the process. Watch the full interview with Sharfstein at Bioprocess Online or wherever you get your podcasts: bioprocessonline.com/doc/str…

As the cost of labor and materials falls, Dropulić makes the case that distributed manufacturing has never been more in reach. bioprocessonline.com/doc/clo…

Distance makes a quantifiable difference that POC manufacturing can solve, writes Boro Dropulić. For people in poverty living 50 miles-plus from academic medical centers, "each additional 10 miles lowers their likelihood of getting CAR-T therapy by 6%."

FDA's on-again-off-again policy for CRL release indicates "a general lack of clarity about what the FDA’s campaign for 'radical transparency' should look like in practice," writes @joshcmorrison of @1daysooner. bioprocessonline.com/doc/an-…

Futuristic vision or imminent reality? On Nov. 17, panelists from Sanofi, Octapharma, and PQE Group will discuss what it takes to move from automation to predictive control — and how soon we might see truly autonomous manufacturing. Register for free: event.on24.com/wcc/r/5512381…


War in the Gulf, tariffs up to 100%, and attacks on clinical trial data have a direct effect on most analytical disciplines but to varying degrees. Here's how one analyst describes the impact of global disruption on analytics.

The higher the DAR, the better, right? Not so fast. When developing ADCs, high DAR doesn't always mean a better drug. As Robert Dream explains, more payload can lead to problems like hydrophobicity and aggregation. bioprocessonline.com/doc/eng…